A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.

Targeted protein degradation is becoming more and more important in the field of drug development. Compared with proteasomal-based degraders, lysosomal-based degraders have a broader target spectrum of targets, which have been demonstrated to have great potential, especially in degrading undruggable proteins. Recently, we developed a programmable and facile screening PROTAC development platform based on peptide self-assembly termed split-and-mix PROTAC (SM-PROTAC). In this study, we applied this technology for the development of lysosome-based degraders, named a split-and-mix chaperone-mediated autophagy-based degrader (SM-CMAD). We successfully demonstrated SM-CMAD as a universal platform by degrading several targets, including ERα, AR, MEK1/2, and BCR-ABL. Different from other lysosomal-based degraders, SM-CMAD was capable of facile screening with programmable ligand ratios. We believe that our work will promote the development of other multifunctional molecules and clinical translation for lysosomal-based degraders.

• Publication year

  2024

• Venue

  ACS Chemical Biology

• Publication date

  2024-04-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acschembio.4c00092PMID 38662199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective Protein of Interest Degradation through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

  2023cited by this paper
• Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias

  2023cited by this paper
• Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach.

  2023cited by this paper
• Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

  2023cited by this paper
• The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system

  2022cited by this paper
• Identification of an autoinhibitory, mitophagy-inducing peptide derived from the transmembrane domain of USP30

  2022cited by this paper
• PROTAC targeted protein degraders: the past is prologue

  2022cited by this paper
• Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR

  2022cited by this paper
• Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)

  2022cited by this paper
• Targeted protein degradation: mechanisms, strategies and application

  2022cited by this paper
• Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery.

  2021cited by this paper
• Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras.

  2021cited by this paper
• Targeting lipid droplets for autophagic degradation by ATTEC

  2021cited by this paper
• Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.

  2021cited by this paper
• Lysosome-targeting chimaeras for degradation of extracellular proteins

  2020cited by this paper
• Targeting selective autophagy by AUTAC degraders

  2020cited by this paper
• AUTACs: Cargo-Specific Degraders Using Selective Autophagy.

  2019cited by this paper
• PROTACs: great opportunities for academia and industry

  2019cited by this paper
• Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.

  2019cited by this paper
• Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

  2019cited by this paper
• HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity

  2018cited by this paper
• Fmoc Solid-Phase Peptide Synthesis.

  2015cited by this paper
• Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation

  2014cited by this paper
• Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein

  2010cited by this paper
• Formation of Closed-Cage Nanostructures by Self-Assembly of Aromatic Dipeptides

  2004cited by this paper

• PROTAC-based protein degradation: a window of opportunity for melanoma therapy

  2026influential citation
• Molecular engineering of lysosome-based degraders unveils a rapidly expanding therapeutic strategy.

  2026cites this paper
• Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists.

  2025cites this paper
• Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

  2025cites this paper
• Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia

  2025cites this paper
• EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

  2025cites this paper
• Targeted RNA Degradation via LipoSM-RiboTAC Nanoparticles: A Versatile Platform for Cancer Therapy.

  2025cites this paper
• Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia.

  2025cites this paper
• De Novo Design of Hexamer-Linker Dual-Action Nano-PROTAC for Tumor-Specific Ferroptosis.

  2025cites this paper
• Deacetylation of HSC70 by SIRT2 promotes chaperone mediated autophagy

  2025cites this paper
• Small-Molecule Ligands Targeting Lysosome-Shuttling Receptors and the Emerging Landscape of Lysosome-Targeting Chimeras.

  2025cites this paper
• Research Advances in Chaperone-Mediated Autophagy (CMA) and CMA-Based Protein Degraders.

  2025cites this paper
• Autophagy‐Mediated Targeted Protein Degradation

  2024cites this paper